A Multi-Center, Two-Stage, Open-Label, Prospective, Fellow-Eye Active-Comparator-Controlled Phase 2a Study of ENV515 (Travoprost) Intracameral Implant in Subjects With Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma

Trial Profile

A Multi-Center, Two-Stage, Open-Label, Prospective, Fellow-Eye Active-Comparator-Controlled Phase 2a Study of ENV515 (Travoprost) Intracameral Implant in Subjects With Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 May 2017

At a glance

  • Drugs Travoprost (Primary)
  • Indications Open-angle glaucoma
  • Focus Therapeutic Use
  • Sponsors Envisia Therapeutics
  • Most Recent Events

    • 05 May 2017 Interim analysis of low dose ENV515 travoprost XR with 11-month duration followed by dose escalation and 28-day efficacy evaluation of high-dose ENV515 will be presented at the Association for Research in Vision and Ophthalmology's (ARVO) Annual Meeting.
    • 03 Feb 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Jul 2017.
    • 03 Feb 2017 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top